abstract |
The present invention relates to specific FGF-R4 receptor antagonist molecules that allow inhibition of receptor activity. Antagonists are, in particular, FGF-R4 specific antibodies that allow inhibition of receptor activity. The present invention also relates to the therapeutic use of antibodies, particularly in the field of angiogenesis and in the treatment of certain types of cancer. |